LAG3 and breast cancer: Increased TILs were described with reduced proliferative suppression in neoadjuvant, endocrine-treated, postmenopausal, ER+ breast cancer [25] with increased levels of immune checkpoint components IDO1, PD-1 and LAG3 described with AI-resistant proliferation in luminal B cancer [27].